Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.85 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | DPP4 | P27487 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
| ▸ | RELA | Q04206 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383857 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL25221544 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL2287800 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL633058 | 0.95 | KMT2A (0.90) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL633057 | 0.95 | KMT2A (0.90) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL30383344 | 0.95 | KMT2A (0.90) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL25195226 | 0.92 | CYP3A4 (0.85) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL5432735 | 0.92 | ABCG2 (1.00) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL25196877 | 0.92 | CYP3A4 (0.85) | CYP3A4MAPTKMT2ATDP1MEN1 | |
| SCHEMBL5432732 | 0.92 | ABCG2 (1.00) | CYP3A4MAPTKMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189310-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2011-08-04 | — | — | US | claimed |
| WO-2010042728-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2010-04-15 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130203822-A1 | COMPOUNDS FOR TREATMENT OF TUMORS BEARING DEREGULATED MYC ONCOPROTEINS | QUATTRONE ALESSANDRO (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20110189310-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010042728-A1 | SMALL MOLECULE MODULATORS OF PRONGF UPTAKE | CORNELL UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| US-4605674-A | VIRICIDES | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP3A4 17/4885MAPT 4566/4885KMT2A 4362/4885 |
| US-20130203822-A1 | COMPOUNDS FOR TREATMENT OF TUMORS BEARING DEREGULATED MYC ONCOPROTEINS | MYC, MYCBP, BCOR | CYP3A4 2191/4885MAPT 4756/4885KMT2A 1016/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CYP3A4 928/4885MAPT 3297/4885KMT2A 2792/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CYP3A4 1589/4885MAPT 3512/4885KMT2A 3188/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CYP3A4 1589/4885MAPT 3512/4885KMT2A 3188/4885 |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | NFE2, NFE2L2, UBE2N | CYP3A4 2576/4885MAPT 1707/4885KMT2A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.